Pioneering sustainable transatlantic transport to cut emissions in pharmaceutical supply chains Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using…
WHO Expands Essential Medicines Lists to Include Landmark Treatments for Cancer, Diabetes, and Other Major Disease The World Health Organization (WHO) has announced a major update to its Model Lists of Essential Medicines (EML) and the Essential Medicines for Children…
BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biotechnology company, announced a significant financial and strategic transaction involving…
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Early-Stage Lung Cancer, Expanding Its Role in Perioperative NSCLC Treatment BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to transforming cancer care through next-generation immunotherapy,…
BeOne Medicines Showcases Bold Vision and Expansive Oncology Pipeline at 2025 R&D Day BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its highly anticipated Research and Development (R&D) Day. The event spotlighted…
BeOne Medicines Receives Positive CHMP Opinion for New Film-Coated Tablet Formulation of BRUKINSA® (zanubrutinib), Paving the Way for European Market Approval BeOne Medicines Ltd. a globally operating oncology-focused biopharmaceutical company, has taken a significant step forward in expanding patient access…
Revolution Medicines Secures $2 Billion Strategic Funding from Royalty Pharma to Accelerate Development and Global Commercialization of RAS(ON) Inhibitor Portfolio Revolution Medicines, a leading late-stage oncology company focused on precision therapies for genetically defined cancers, has announced a landmark funding…
Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical industry, announced a transformative agreement with Revolution Medicines, Inc., securing…
BeOne Medicines Officially Launches Following Redomiciliation to Switzerland, Ushering in a New Era of Global Oncology Leadership BeOne Medicines Ltd. formerly known as BeiGene, Ltd., has officially entered a transformative new chapter in its corporate journey with the announcement of…
Revolution Medicines Shares Early Zoldonrasib Data in KRAS G12D NSCLC at 2025 AACR Revolution Medicines, Inc. a late-stage clinical oncology company committed to developing targeted therapies for patients with RAS-addicted cancers, today unveiled new clinical data on zoldonrasib (RMC-9805), a…
EveryONE Medicines Names Michelle L. Mellion, MD, as New Chief Medical Officer EveryONE Medicines, a trailblazing biotech company transforming the way individualized therapies are developed for children suffering from ultra-rare and life-threatening neurodegenerative diseases, has announced the appointment of Michelle…
California Advocates Urge Greater Access to Plasma-Derived Medicines In a compelling call to action, the California Rare Disease Access Coalition, Hemophilia Council of California, and the Plasma Protein Therapeutics Association (PPTA) have joined forces to advocate for the swift passage…